University of Cincinnati researchers say they have discovered a new therapy for transplant patients; targeting the antibody-producing plasma cells that can cause organ rejection. Steve Woodle, MD, and colleagues found that a cancer drug. bortezomib, that is used to treat
multiple myeloma, or cancer of the plasma cells, is also effective in treating rejection episodes caused by antibodies that target transplanted kidneys and reversing rejection episodes that did not respond to standard therapies.
B-lymphocytes, or B cells, play a large role in the humoral immune response by making immune proteins that attack transplanted organs.